Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) have been assigned a consensus rating of “Hold” from the six analysts that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $21.00.

CRBP has been the topic of several recent analyst reports. Cantor Fitzgerald set a $24.00 price target on Corbus Pharmaceuticals Holdings and gave the company a “buy” rating in a report on Wednesday, August 9th. Noble Financial reaffirmed a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a report on Wednesday, August 9th. BidaskClub raised Corbus Pharmaceuticals Holdings from a “sell” rating to a “hold” rating in a report on Saturday, July 8th. Finally, ValuEngine cut Corbus Pharmaceuticals Holdings from a “hold” rating to a “sell” rating in a report on Wednesday.

ILLEGAL ACTIVITY WARNING: “Analysts Set Corbus Pharmaceuticals Holdings, Inc. (CRBP) Target Price at $21.00” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/09/16/analysts-set-corbus-pharmaceuticals-holdings-inc-crbp-target-price-at-21-00.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of Corbus Pharmaceuticals Holdings by 24.5% during the 2nd quarter. Vanguard Group Inc. now owns 1,563,408 shares of the biopharmaceutical company’s stock valued at $9,850,000 after buying an additional 307,979 shares in the last quarter. State Street Corp raised its holdings in shares of Corbus Pharmaceuticals Holdings by 2,998.2% during the 2nd quarter. State Street Corp now owns 588,662 shares of the biopharmaceutical company’s stock valued at $3,708,000 after buying an additional 569,662 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Corbus Pharmaceuticals Holdings by 814.3% during the 2nd quarter. Northern Trust Corp now owns 482,337 shares of the biopharmaceutical company’s stock valued at $3,039,000 after buying an additional 429,584 shares in the last quarter. Raymond James Financial Services Advisors Inc. raised its holdings in shares of Corbus Pharmaceuticals Holdings by 5.5% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 426,280 shares of the biopharmaceutical company’s stock valued at $2,686,000 after buying an additional 22,394 shares in the last quarter. Finally, Artal Group S.A. purchased a new position in shares of Corbus Pharmaceuticals Holdings during the 2nd quarter valued at about $1,575,000. 31.78% of the stock is currently owned by institutional investors.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) traded down 0.74% during mid-day trading on Wednesday, hitting $6.75. The stock had a trading volume of 744,499 shares. The firm’s market cap is $338.99 million. Corbus Pharmaceuticals Holdings has a 52 week low of $4.65 and a 52 week high of $10.78. The company’s 50 day moving average price is $6.47 and its 200 day moving average price is $6.96.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.04. Corbus Pharmaceuticals Holdings had a negative return on equity of 107.10% and a negative net margin of 1,001.77%. The firm had revenue of $0.35 million for the quarter, compared to analysts’ expectations of $0.50 million. Analysts anticipate that Corbus Pharmaceuticals Holdings will post ($0.66) earnings per share for the current year.

About Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.